Esperion Therapeutis.Inc. buy Global_Player
Summary
This prediction ended on 08.08.21 with a price of €12.11. With a performance of -6.99%, the BUY prediction by Global_Player finished with a loss. Global_Player has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 2.142% | 2.142% | 59.823% | -44.949% |
| iShares Core DAX® | 0.224% | 2.457% | 21.634% | 71.886% |
| iShares Nasdaq 100 | 0.371% | -0.320% | 5.422% | 113.046% |
| iShares Nikkei 225® | 0.972% | -0.829% | 15.333% | 47.267% |
| iShares S&P 500 | 0.417% | -0.157% | 3.125% | 68.687% |
According to Global_Player what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by Global_Player for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Global_Player for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
29.08.25
29.08.26
15.09.25
Esperion Therapeutis.Inc.
26.02.25
26.02.26
01.03.25
Esperion Therapeutis.Inc.
25.04.24
25.04.25
27.04.24
Esperion Therapeutis.Inc.
28.08.23
28.08.24
30.08.23
Esperion Therapeutis.Inc.
07.12.22
07.12.23
11.12.22


